CoChat

Durability of symptomatic responses obtained with adjunctive vagus nerve stimulation in treatment-resistant depression

Open access

The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.

Abstract

Objective: To compare the durations of response achieved with adjunctive vagus nerve stimulation (VNS + TAU) vs treatment as usual (TAU) alone in treatment-resistant depression (TRD) over a 5-year period in the TRD registry. Materials and methods: Data from 271 participants on TAU and 328 participants on VNS + TAU were analyzed. Response was defined as ≥50% decrease in baseline Montgomery–Åsberg Depression Rating Scale (MADRS) score at postbaseline visit and was considered retained until the decrease was <40%. MADRS was obtained quarterly in year 1 and biannually thereafter. Time-to-events were estimated using Kaplan–Meier method and compared using log-rank test. HR was estimated using Cox proportion hazard model. Results: In the VNS + TAU arm, 62.5% (205/328) of participants had a first response over 5 years compared with 39.9% (108/271) in TAU. The time to first response was significantly shorter for VNS + TAU than for TAU ( P <0.01). For responders in the first year, median time to relapse from first response was 10.1 months (Q1=4.2, Q3=31.5) for VNS + TAU vs 7.3 months (Q1=3.1, Q3=17.6) for TAU ( P <0.01). HR=0.6 (95% CI: 0.4, 0.9) revealed a significantly lower chance for relapse in VNS + TAU. Probability of retaining first response for a year was 0.39 (0.27, 0.51) for TAU and 0.47 (0.38, 0.56) for VNS + TAU. Timing of the onset of the response did not impact the durability of the response. Conclusion: VNS therapy added to TAU in severe TRD leads to rapid onset and higher likelihood of response, and a greater durability of the response as compared to TAU alone. Keywords: depressive disorder, treatment-resistant depression, vagus nerve stimulation, longitudinal study, durability of response

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ndt.s196665

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 A Kaplan–Meier plot demonstrates time to first response among 328 participants in the VNS + TAU group and 271 participants in the TAU group. Notes: Time to first response was defined as the time from baseline to the first visit with a reduction in MADRS score of ≥50% compared to baseline. Median time to the first response was 18.1 months (Q1=6.9, Q3=49.1) for VNS + TAU participants compared to 49.1 months (Q1=12.3, Q3= not estimable) for TAU participants. Abbreviations: MADRS, Montgomery–Åsberg Depression Rating Scale; TAU, treatment as usual; VNS, vagus nerve stimulation.
Figure 1 A Kaplan–Meier plot demonstrates time to first response among 328 participants in the VNS + TAU group and 271 participants in the TAU group. Notes: Time to first response was defined as the time from baseline to the first visit with a reduction in MADRS score of ≥50% compared to baseline. Median time to the first response was 18.1 months (Q1=6.9, Q3=49.1) for VNS + TAU participants compared to 49.1 months (Q1=12.3, Q3= not estimable) for TAU participants. Abbreviations: MADRS, Montgomery–Åsberg Depression Rating Scale; TAU, treatment as usual; VNS, vagus nerve stimulation.CC BY-NC · PubMed Central
Figure 2 A Kaplan–Meier plot for durability of the first response that occurred within the first year. Notes: Duration of first response was defined as the time from first response to the first visit when reduction in MADRS score was <40% compared to baseline (ie, relapse). Median time to relapse from first response in first year was 10.1 months (Q1=4.2, Q3=31.5) for VNS + TAU and 7.3 months (Q1=3.1, Q3=17.6) for TAU. Abbreviations: MADRS, Montgomery–Åsberg Depression Rating Scale; TAU, treatment as usual; VNS, vagus nerve stimulation.
Figure 2 A Kaplan–Meier plot for durability of the first response that occurred within the first year. Notes: Duration of first response was defined as the time from first response to the first visit when reduction in MADRS score was <40% compared to baseline (ie, relapse). Median time to relapse from first response in first year was 10.1 months (Q1=4.2, Q3=31.5) for VNS + TAU and 7.3 months (Q1=3.1, Q3=17.6) for TAU. Abbreviations: MADRS, Montgomery–Åsberg Depression Rating Scale; TAU, treatment as usual; VNS, vagus nerve stimulation.CC BY-NC · PubMed Central
Figure 3 A Kaplan–Meier plot for durability of first response in the first year for VNS + TAU participants by visit. Note: The trend in the probability of retaining the first response beyond 1 year was higher in the early responders (ie, those who first responded at 3 or 6 months after VNS initiation) compared with the late responders (ie, those who first responded at 9 or 12 months after VNS initiation). Abbreviations: TAU, treatment as usual; VNS, vagus nerve stimulation.
Figure 3 A Kaplan–Meier plot for durability of first response in the first year for VNS + TAU participants by visit. Note: The trend in the probability of retaining the first response beyond 1 year was higher in the early responders (ie, those who first responded at 3 or 6 months after VNS initiation) compared with the late responders (ie, those who first responded at 9 or 12 months after VNS initiation). Abbreviations: TAU, treatment as usual; VNS, vagus nerve stimulation.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. [7]AHRQ Technology Assessment Program: Definition of Treatment-Resistant Depression in the Medicare Population. Project ID: PSYT0816 Agency for Healthcare Research and Quality. US Department of Health and Human Services 2018 Available from: https://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id105TA.pdf Accessed April 18, 2018 30260611

Cited by

See all 44

Metadata

Authors
Kumar, A., Bunker, M. T., Aaronson, S. T., Conway, C. R., Rothschild, A. J., Mordenti, G., & Rush, A. J.
Affiliations
  • LivaNova (United States) (US)
  • Washington University in St. Louis (US)
  • Sheppard and Enoch Pratt Hospital (US)
  • University of Massachusetts Chan Medical School (US)
  • National University of Singapore (SG)
Corresponding author
Kumar, Arun
Venue
Neuropsychiatric Disease and Treatment
Published
2019-02
Volume
Volume 15
Pages
457-468
ISSN
  • 1176-6328 (ISSN-L)
  • 1178-2021
OpenAlex
W2912354242
Cited by
44
References
23
Citations by year
2026: 6 · 2025: 5 · 2024: 5 · 2023: 6 · 2022: 5 · 2021: 6 · 2020: 9 · 2019: 2
FWCI
2.42
Type
journal article
Language
en
Open access
Locations
  • Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, other-oa)
  • eScholarship@UMassChan (submittedVersion, cc-by-nc)
  • National University of Singapore (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
  • American Foundation for Suicide Prevention
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • Sanofi
  • Stanley Medical Research Institute
  • Foundation for Barnes-Jewish Hospital
  • University of Texas Southwestern Medical Center
  • Sunovion
  • LivaNova
  • Neurocrine Biosciences
  • Sage Therapeutics
  • Assurex Health
  • NeoSync
  • National Institutes of Health
  • Allergan
  • National Institute of Mental Health
  • Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine in St. Louis
Topics
  • Life Sciences › Neuroscience › Neurology › Vagus Nerve Stimulation Research
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords
vagus nerve stimulation, treatment-resistant depression, adjunctive therapy, durability of response, relapse, time to response, usual care, severe depression, longitudinal outcomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.